FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell…
- Galderma Announces FDA Approval of Restylane® Lyft For Midface Injection via Cannula
- Statement from FDA Commissioner Scott Gottlieb, M.D., on new agency actions to further deter 'gaming' of the generic drug approval process by the use of citizen petitions
- AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.